IEPA 11 has ended
Back To Schedule
Wednesday, October 10 • 2:15pm - 2:25pm
Oral 13, Talk 8. "Early non-response to antipsychotic medication in adolescents with first-episode psychosis is a reliable predictor of ultimate non-response and non-remission: Results from the 12-week TEA trial"

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Anne Katrine Pagsberg1, Pia Jeppesen1, Dea Gowers Klauber1, Karsten Gjessing Jensen1, Ditte Rudå1, Jens Richardt M. Jepsen1, Birgitte Fagerlund1, Amanda Krogmann2, Laura von Hardenberg2, Anders Fink-Jensen1, Christoph U Correll2,3, Britta Galling2; 1Copenhagen University Hospitals, 2Charité Universitätsmedizin, 3Hofstra University
Objective: To evaluate whether early response/non-response (ER/ENR) to antipsychotics can predict ultimate response/non-response (UR/UNR) and remission/non-remission, and to compare the Positive and Negative Syndrome Scale (PANSS)-30-items to the PANSS-6-items and Clinical Global Impressions Scale (CGI) regarding prediction of response/non-response and remission/non-remission in youth with psychosis. Methods:  Data from 12-week, double-blinded, randomized trial of aripiprazole (2.5-20 mg/day) versus quetiapine (50-600 mg/day) in adolescents with first-episode psychosis (age=12-17 years). Therapeutic antipsychotic doses were reached at day 9. ER definition: ≥20% symptom reduction (PANSS-30) at week-2 or week-4 (ER2/4) (or: “≥minimally improved” (CGI-I) and ≥20% symptom reduction (PANSS-6)). UR definition: ≥50% symptom reduction. Remission definition: “Andreasen criteria”. Analyses: positive/negative predictive values (PPV/NPV), and logistic regression to identify moderators/mediators of UR/UNR and remission/non-remission. Results:  Patients (n=87; age=15.2±1.4 years; male=35.6%) had a mean 32.0±28.2% symptom decrease, most pronounced within the first two weeks. UR and remission rates were low (28.7%; 19.5%). ER2/ER4 could not predict UR (ER2: PPV=40.0%, ER4: PPV=38.2%) and remission (ER2: PPV=27.5%, ER4: PPV=27.3%), while ENR reliably predicted UNR (ENR2: NPV=80.0%, ENR4: NPV=87.5%) and non-remission (ENR2: NPV=84.4%, ENR4: NPV=90.6%). Besides ER/ENR-status, no significant demographic, illness or treatment variables were significant moderators/mediators of endpoint outcomes. PANSS-6 had similar predictive significance as PANSS-30 for non-response/non-remission. Outcomes were heterogeneous using CGI. Conclusion: Clinical treatment decisions should be informed by standardized assessments. A <20% reduction of PANSS-6-items at week-2 and, even more so, at week-4 is a feasible and clinically relevant alternative to PANSS-30 assessments to reliably predict 12-week non-response/non-remission. In patients with ENR4, consider antipsychotic switch.

Wednesday October 10, 2018 2:15pm - 2:25pm EDT
Staffordshire Westin Copley Place, third floor

Attendees (8)